<s>[INST] context: (Safety and comparisons with other medicines) (43-Bennett & Brown) (61-62-GG)Pharmacokinetics - what the body does to the drag. This refers to movements of the drug in and alteration of the drug by the body; includes absorption, distribution, binding/localization/storage, biotransformation and excretion of the drug (1-KDT)* Post licensing (marketing) studies of safety and comparisons with other medicines (43-BB)Pharmacodynamics - What the drug does to the body. This includes physiological and biochemical effects of drugs and their mechanism of action at macromolecular/subcellular/ organ system levels.Post marketing detection of adverse reaction - several strategies exist to detect adverse reactions after marketing of a drug, but debate continues about the most efficient and effective method. Formal approaches for estimation of the magnitude of an adverse drug effect are the follow-up or "cohort" study of patients who are receiving a particular drug, the "case control" study where the potential for a drug to cause a particular disease is assessed, and meta-analysis of pre and post marketing (61-62-Goodman & Gillman's 10th) [/INST] question: The aim of post marketing pharmacokinetics is | options: A: Efficacy of the drug B: Dosage of the drug C: Deals with alteration of the drug includes absorption, distribution, binding / storage D: Safety and comparisions with other medicines | answer: D </s>